Home/Pipeline/KIVU-202

KIVU-202

Solid tumors

Development CandidateActive

Key Facts

Indication

Solid tumors

Phase

Development Candidate

Status

Active

Company

Kivu Bioscience

About Kivu Bioscience

Kivu Bioscience is a private, pre-revenue biotech founded in 2018, advancing a pipeline of novel antibody-drug conjugates (ADCs) for solid tumors. The company's core technology is built on Synaffix's GlycoConnect™ site-specific conjugation platform, which it combines with proprietary linkers and potent payloads to aim for best-in-class product profiles. With a seasoned leadership team and backing from prominent life science investors like Novo Holdings and HealthCap, Kivu is progressing multiple programs toward clinical development to address significant unmet needs in oncology.

View full company profile

Therapeutic Areas

Oncology

Other Solid tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed